“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, ...

"I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.

Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds reported to be useful for the treatment of cancer, autoimmune and ...